We provide you with 20 years of free, institutional-grade data for CCXI stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CCXI. Explore the full financial landscape of CCXI stock.
| Reported Date | CIK | Ticker | Type |
|---|
ChemoCentryx, Inc(NASDAQ:CCXI) 
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibito...
Website: http://www.chemocentryx.com
Founded: 1996
Full Time Employees: 133 (May 2021)
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about CCXI stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.